Document is current
Any future updates will be listed below
-
Authors
Wang, Tao
Li, Wenxuan
Wu, Yuelan
You, Liping
Zheng, Chao
Zhang, Jinghao
Qu, Lihong
Sun, Xuehua
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82074336, 82074336, 82074336, 82074336, 82074336, 82074336, 82074336, 82074336)
Program of Shanghai 2020 Science and Technology Innovation Action Plan (20S21901600, 20S21901600, 20S21901600, 20S21901600, 20S21901600, 20S21901600, 20S21901600, 20S21901600)
2022 Health Leading Talents of Shanghai Health Commission (2022LJ013, 2022LJ013, 2022LJ013, 2022LJ013, 2022LJ013, 2022LJ013, 2022LJ013, 2022LJ013)
The key subject group of TCM liver disease will be established in Pudong New Area in 2022 (PWZxq2022-04, PWZxq2022-04, PWZxq2022-04, PWZxq2022-04, PWZxq2022-04, PWZxq2022-04, PWZxq2022-04, PWZxq2022-04)
2022 Shanghai TCM high-level Talents Leading Plan to Xuehua Sun
- License Information
-
More Information
Article History
Received: 3 September 2024
Accepted: 18 November 2024
First Online: 19 December 2024
Declarations
:
: The study involving human participants and HCC mouse models was reviewed and approved with the permission of the ethics committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Informed consent was diligently secured from all participants involved in the study.
: Not applicable.
: The authors declare no competing interests.
